ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 0437 • ACR Convergence 2023

    Comparative Safety of Biologic and Targeted Synthetic Disease Modifying Anti-Rheumatic Drugs for Cardiovascular Outcomes in Rheumatoid Arthritis

    Xavier Sendaydiego1, Laura Gold2, K Wysham3, Jean liew4, Maureen Dubreuil5, James Andrews1, Pankti Reid6, David Liew7, Radjiv Goulabchand8, Abha Singh9, Grant Hughes1, Mathilde Pioro1, Jeffrey Sparks10, Jeffrey Jarvik2, Siddharth Singh9 and Namrata Singh11, 1University of Washington, Seattle, WA, 2Department of Radiology and University of Washington Clinical Learning, Evidence, and Research (CLEAR) Center for Musculoskeletal Disorders, Seattle, WA, 3VA Puget Sound/University of Washington, Seattle, WA, 4Boston University, Boston, MA, 5Department of Rheumatology, Boston University School of Medicine, Milton, MA, 6University of Chicago Medical Center, Chicago, IL, 7Austin Health, Heidelberg, Australia, 8St. Eloi Hospital, Department of Internal Medicine and Multi-Organic Diseases, Montpellier, France, 9University of California San Diego, San Diego, CA, 10Division of Rheumatology, Inflammation, and Immunity, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, 11University of Washington, Bellevue, WA

    Background/Purpose: Concern has arisen over the safety of Janus kinase inhibitors (JAKi) regarding cardiovascular (CV) outcomes in patients with rheumatoid arthritis (RA) with CV risk…
  • Abstract Number: 0466 • ACR Convergence 2023

    Impact of Postpartum on Patients with Inflammatory Rheumatic Diseases: The P2Rheum Study

    Marie Hornez1, Anna Molto2, Maxime Leroy3, beatrice banneville4, Rakiba Belkhir5, elodie chauvet6, Marion Couderc7, Emanuelle Dernis8, sandra Desouches9, Valerie Devauchelle10, Aline Frazier-Mironer11, Laure Gossec12, elisabeth Gervais13, Hubert Marotte14, Christophe Richez15, Jeremie SELLAM16, Raphaele Seror17, Véronique Le Guern18, Gaelle Guettrot-Imbert18, Nathalie Costedoat-Chalumeau19, Rene-Marc Flipo20 and Jean-Guillaume Letarouilly21, 1University of Lille, Lille, France, 2HOPITAL COCHIN AP-HP, Service de Rhumatologie, Paris, France, 3CHU Lille - Department of Biostatistics, Lille, France, 4Sorbonne universite and Pitié Salpêtrière Hospital, la Garenne Colombes, France, 5Assistance Publique-Hôpitaux de Paris, Hôpital Bicêtre, Le Kremlin-Bicêtre, France, 6CH Perpignan, Perpignan, France, 7CHU Gabriel Montpied, Clermont Ferrand, France, 8CH Le Mans, Le Mans, France, 9Hôpital Saint Antoine, Assistance Publique Hôpitaux de Paris, Paris, France, 10UBO, Brest, France, 11APHP Lariboisiere Hospital, Paris, France, 12Sorbonne Université and Pitié Salpêtrière Hospital, Paris, France, 13CHU Poitiers, Poitiers, France, 14CHU Saint-Etienne, Saint-Etienne, France, 15Université de Bordeaux, Bordeaux, France, 16Sorbonne Université APHP, Paris, France, 17University Hospital Paris Saclay, Le Kremlin-Bicêtre, France, 18APHP Hôpital Cochin, Paris, France, 19Inserm DR Paris 5, Paris, France, 20La Lettre du Rhumatologue, Paris, France, 21CHU Lille, Lille, France

    Background/Purpose: There are limited data on the impact of the postpartum period (PP) on the activity of inflammatory rheumatic disorders (IRD), and the data available…
  • Abstract Number: 0440 • ACR Convergence 2023

    Baseline T Cell and B Cell-related Markers and HLA-DRB1 Shared Epitope Alleles Predict the Therapeutic Efficacy of Abatacept in Patients with Moderate to Severe Rheumatoid Arthritis

    Ting Wang1, Natalia V. Giltiay2, Christian Lood2 and Bobby Kwanghoon Han2, 1University of Washington, Seattle, WA, 2Division of Rheumatology, University of Washington, Seattle, WA

    Background/Purpose: Abatacept, a CTLA-4-Ig fusion protein, is widely used as a treatment for rheumatoid arthritis (RA). However, data on predictive biomarkers associated with therapeutic response…
  • Abstract Number: 0487 • ACR Convergence 2023

    A Comparative Study of Serositis Between Inpatients with Psoriatic Arthritis and Rheumatoid Arthritis

    Ashmia Saif1, Priyanka Dongare2, Meghan Beard3, Yunhan Liao4, Xiaoyue Zhang4, Qingping Yao5 and Asha Patnaik6, 1Stony Brook University Hospital, Syosset, NY, 2Stony Brook University Hospital, Highland, NY, 3Stony Brook Southampton, Moriches, NY, 4Biostatistical Consulting Core - Renaissance School of Medicine at Stony Brook University, Stony Brook, NY, 5Stony Brook University, Stony Brook, NY, 6Stony Brook University Medical Center, East Setauket, NY

    Background/Purpose: Autoimmune diseases such as rheumatoid arthritis (RA) and psoriatic arthritis (PsA) can causes erositis including pericarditis and pleuritis. However, the rate of serositis in…
  • Abstract Number: 0479 • ACR Convergence 2023

    Exploring Reproductive Experiences with Women Enrolled in the Vasculitis Pregnancy Registry

    Catherine Sims1, Christine Yeung2, Heather Tam3, Joyce Kullman4, Amanda Eudy5, Renee Borchin6, Cristina Burroughs6, Megan Clowse7 and Peter Merkel2, 1Duke University School of Medicine, Durham, NC, 2University of Pennsylvania, Philadelphia, PA, 3Vasculitis Patient Powered Research Network, Stanford, CA, 4Vasculitis Foundation, Kansas City, MO, 5Duke University, Raleigh, NC, 6University of South Florida, Tampa, FL, 7Duke University, Chapel Hill, NC

    Background/Purpose: There are limited data on the reproductive health and experiences of women with vasculitis. This study engaged women with vasculitis to understand their perspectives…
  • Abstract Number: 0438 • ACR Convergence 2023

    Association Between Methotrexate Use and Lymphoma in Rheumatoid Arthritis: A Systematic Literature Review

    Swetha Ann Alexander1, Gordon Starkebaum2, Diana Louden2, Grant Hughes2 and Namrata Singh3, 1University of Utah Health, Salt Lake City, UT, 2University of Washington, Seattle, WA, 3University of Washington, Bellevue, WA

    Background/Purpose: Rheumatoid Arthritis (RA) patients have an increased risk of developing lymphoma compared to the general population. This increased risk is believed to be linked…
  • Abstract Number: 0497 • ACR Convergence 2023

    Effects and Tolerability of Low to Moderate Biomechanical Stress During Leisure Sport Activity in Patients with Psoriasis and Psoriatic Arthritis

    Filippo Fagni1, Melek Yalcin Mutlu1, Ioanna Minopoulou1, Selahattin Alp Temiz2, Manuel Krieter3, Georg Schett4, Arnd Kleyer5, David Simon1 and Axel Hueber6, 1Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg & Universitätsklinikum Erlangen, Department of Internal Medicine 3 - Rheumatology and Immunology / Deutsches Zentrum Immuntherapie, Erlangen, Germany, 2University Hospital Erlangen and Friedrich-Alexander University (FAU) Erlangen-Nürnberg, Department of Internal Medicine 3 - Rheumatology and Immunology, Erlangen, Germany, 3Department of Dermatology, Klinikum Nürnberg, Paracelsus Medical University, Nürnberg, Germany, 4Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany, 5University Hospital Erlangen, Erlangen, Germany, 6Division of Rheumatology, Klinikum Nürnberg, Paracelsus Medical University / Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg & Universitätsklinikum Erlangen, Department of Internal Medicine 3 - Rheumatology and Immunology, Nürnberg, Germany

    Background/Purpose: International guidelines advise physical activity as complementary measure to drug treatment for patients with RA. However, this can hardly be extrapolated for PsA, for which…
  • Abstract Number: 0485 • ACR Convergence 2023

    Sex and Treatment-associated Outcomes in Patients with Active Psoriatic Arthritis Treated with Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in a Phase 2 Trial

    Lihi Eder1, Alexis R Ogdie2, Subhashis Banerjee3, Miroslawa Nowak3, Thomas Lehman4 and Philip J. Mease5, 1Women’s College Research Institute, Division of Rheumatology, University of Toronto, Toronto, ON, Canada, 2University of Pennsylvania, Philadelphia, PA, 3Bristol Myers Squibb, Princeton, NJ, 4Bristol Myers Squibb, Philadelphia, PA, 5Swedish Medical Center/Providence St. Joseph Health and University of Washington School of Medicine, Seattle, WA

    Background/Purpose: Sex differences have been reported in pathophysiology, clinical manifestations, and treatment responses in several rheumatic diseases, including psoriatic arthritis (PsA).1 Although PsA is equally…
  • Abstract Number: 0473 • ACR Convergence 2023

    The Number of Rheumatoid Arthritis Patients Who Give up Pregnancy Due to the Disease Is Decreasing

    Ryo Inoue1, Sakiko Isojima1, Toshihiro Matsui2, Shigeto Tohma3 and Nobuyuki Yajima4, 1Division of Rheumatology, Department of Medicine, Showa University School of Medicine, Shinagawa City, Tokyo, Japan, 2NHO Sagamihara National Hospital, Kanagawa, Japan, 3NHO Tokyo National Hospital, Dallas, TX, 4Showa-Universtiy of Medicine, Tokyo, Japan

    Background/Purpose: Biologics have been shown not to be a disruption in pregnancy, and the reproductive health care environment surrounding rheumatoid arthritis patients has improved significantly.…
  • Abstract Number: 0442 • ACR Convergence 2023

    Infliximab Clearance a Predictive Factor of Pharmacokinetic Origin in Relation to Suboptimal Pharmacokinetics and Immunogenicity in United States Based Rheumatology Practices

    Elliot Rosenstein1, Michael Weinblatt2, Annelie Everts-van der Wind3, John Conklin3 and Thierry Dervieux3, 1Institute for Rheumatic & Autoimmune Diseases--Atlantic Health System, Far Hills, NJ, 2Harvard Medical School, Waban, MA, 3Prometheus Laboratories, San Diego, CA

    Background/Purpose: Infliximab (IFX) has become a mainstay of treatment of many different immune-mediated inflammatory diseases. With the wide range of IFX dosing and dosing intervals,…
  • Abstract Number: 0504 • ACR Convergence 2023

    Burden of Disease of Psoriatic Arthritis in Latin America: A Systemic Review of Literature

    Wilson Bautista-Molano1, Linda Ibata2, Susan Martinez2 and Andrea Chacon2, 1University Hospital Fundación Santa Fe de Bogotá, Bogotá, Colombia, 2InValue Health Solutions, Bogotá, Colombia

    Background/Purpose: Psoriatic arthritis (PsA) is a chronic inflammatory pathology that generates a substantial and progressive deterioration of functionality and quality of life. It is associated…
  • Abstract Number: 0471 • ACR Convergence 2023

    Knowledge and Misconceptions About Contraception Among Individuals with Inflammatory Arthritis and Lupus-like Diseases

    Caroline Siegel1, Medha Barbhaiya2, Lucy Masto1, Amaya Smole1, Bessie Stamm1, Jonah Levine1, Sarah Lieber2, Lisa Mandl2, Michael Lockshin2 and Lisa Sammaritano2, 1Hospital for Special Surgery, New York, NY, 2Hospital for Special Surgery, Weill Cornell Medicine, New York, NY

    Background/Purpose: Rheumatologists do not consistently provide contraceptive counseling for patients with systemic rheumatic disease (SRD). As contraception considerations may differ based on SRD, we compared…
  • Abstract Number: 0454 • ACR Convergence 2023

    Rheumatoid Arthritis Disease Activity Indices Assess More Than Inflammation: 29%-36% of Patients with Moderate or High DAS28–ESR or CDAI Have 0 or 1 Swollen Joints, but Positive Screens on MDHAQ FAST4 (fibromyalgia Assessment Screening Tool) And/or MDS2 (MDHAQ Depression Screen) Indices

    Theodore Pincus1, Nicholas Rodwell2 and Rahel Hunter1, 1Rush University Medical Center, Chicago, IL, 2University of New South Wales, Sydney, Australia

    Background/Purpose: Rheumatoid arthritis (RA) therapy is recommended to be intensified according to treat-to-target if DAS28 (disease activity score 28) or CDAI (clinical disease activity index)…
  • Abstract Number: 0511 • ACR Convergence 2023

    Long-term Safety and Tolerability of Bimekizumab in Patients with Axial Spondyloarthritis and Psoriatic Arthritis: Results from Pooled Phase 2b/3 Studies

    Philip J. Mease1, Denis Poddubnyy2, Ana-Maria Orbai3, Richard B. Warren4, Carmen Fleurinck5, Rajan Bajracharya6, Barbara Ink6, Ute Massow7, Vishvesh Shende6, Julie Shepherd-Smith6, Luke Peterson8, Katy White6, Robert BM Landewé9 and Lianne Gensler10, 1Swedish Medical Center/Providence St. Joseph Health and University of Washington School of Medicine, Seattle, WA, 2Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité – Universitätsmedizin Berlin, Berlin, Germany, 3Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, MD, 4Dermatology Centre, Northern Care Alliance NHS Foundation Trust; NIHR Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom, 5UCB Pharma, Oosterzele, Belgium, 6UCB Pharma, Slough, United Kingdom, 7UCB Pharma, Monheim am Rhein, Germany, 8UCB Pharma, Raleigh, NC, 9Amsterdam Rheumatology & Clinical Immunology Center, Amsterdam and Zuyderland MC, Herleen, Netherlands, 10University of California San Francisco, Department of Medicine, Division of Rheumatology, San Francisco, CA

    Background/Purpose: Bimekizumab (BKZ) is a monoclonal IgG1 antibody that selectively inhibits IL‑17F in addition to IL‑17A. A previous analysis of pooled safety data from the…
  • Abstract Number: 0515 • ACR Convergence 2023

    Dose Adjustment of Tumor Necrosis Factor Inhibitors Does Not Correlated with Radiographic Progression in Patients with Ankylosing Spondylitis

    Bon San Koo1, Seo Young Park2, Ji Hui Shin3, Seunghun lee3, kyung bin Joo3 and Tae-Hwan Kim4, 1Inje University Seoul Paik Hospital, Seoul, South Korea, 2Korea National Open University, Seoul, South Korea, 3Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, 4Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea

    Background/Purpose: Among patients with ankylosing spondylitis (AS) treated with tumor necrosis factor (TNF) inhibitors, tapering the dose of TNF inhibitors may be considered for patients…
  • « Previous Page
  • 1
  • …
  • 303
  • 304
  • 305
  • 306
  • 307
  • …
  • 2425
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology